Literature DB >> 18693067

Hypnotic use for insomnia management in chronic obstructive pulmonary disease.

Thomas Roth1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity worldwide. Because of the chronic nature of the disease, optimal care for patients includes successful treatment of comorbidities that accompany COPD, including insomnia. Insomnia symptoms and associated disruption of sleep are prevalent in COPD patients but treatment with traditional benzodiazepines may compromise respiratory function. This review summarizes the efficacy and safety consideration of current drugs available for the treatment of insomnia in COPD patients including benzodiazepines, non-benzodiazepine receptor agonists such as eszopiclone, zolpidem, and zaleplon, sedating antidepressants such as trazodone, and the melatonin receptor agonist ramelteon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18693067     DOI: 10.1016/j.sleep.2008.06.005

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  18 in total

1.  The Use of Benzodiazepine Receptor Agonists and Risk of Respiratory Failure in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Case-Control Study.

Authors:  Su-Jung Chen; Chiu-Mei Yeh; Tze-Fan Chao; Chia-Jen Liu; Kang-Ling Wang; Tzeng-Ji Chen; Pesus Chou; Fu-Der Wang
Journal:  Sleep       Date:  2015-07-01       Impact factor: 5.849

2.  Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder.

Authors:  Lucas M Donovan; Carol A Malte; Laura J Spece; Matthew F Griffith; Laura C Feemster; Steven B Zeliadt; David H Au; Eric J Hawkins
Journal:  Ann Am Thorac Soc       Date:  2019-09

Review 3.  Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management.

Authors:  Rohit Budhiraja; Tauseef A Siddiqi; Stuart F Quan
Journal:  J Clin Sleep Med       Date:  2015-03-15       Impact factor: 4.062

Review 4.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

5.  Cognitive behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of positive sleep and fatigue effects.

Authors:  Mary C Kapella; James J Herdegen; Michael L Perlis; Joan L Shaver; Janet L Larson; Julie A Law; David W Carley
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-11-24

6.  Adverse Respiratory Events Associated With Hypnotics Use in Patients of Chronic Obstructive Pulmonary Disease: A Population-Based Case-Control Study.

Authors:  Wei-Sheng Chung; Ching-Yuan Lai; Cheng-Li Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Benzodiazepine use in COPD: empirical evidence from Norway.

Authors:  Thomas Halvorsen; Pål E Martinussen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-08-27

Review 8.  Sleep Disturbance, Sleep Disorders and Co-Morbidities in the Care of the Older Person.

Authors:  Christine E Mc Carthy
Journal:  Med Sci (Basel)       Date:  2021-05-21

9.  Critical appraisal of ramelteon in the treatment of insomnia.

Authors:  Monique Aj Mets; Kenny R van Deventer; Berend Olivier; Joris C Verster
Journal:  Nat Sci Sleep       Date:  2010-11-10

10.  New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.

Authors:  Rüdiger Hardeland
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.